July 4, 2008

Welcome!

The Pharmacovigilance Project of the American Thyroid Association (ATA) provides a mechanism for physicians and pharmacists to report information about possible adverse events or product availability problems related to thyroid hormone medications.

Levothyroxine (LT4) is the most commonly used medication for thyroid disease and the primary focus of this project, although data on Liothyronine (T3) (alone or in combination with LT4) and Thyroid Extract (Thyroid USP) will also be gathered.  The recent FDA decision to allow substitution among certain levothyroxine products has resulted in confusion among some patients, pharmacists, and doctors.  In some patients, changes between thyroxine formulations could theoretically be associated with adverse clinical outcomes. 

This website has been designed to collect information regarding perceived adverse outcomes related to thyroid medications.  We are very interested in your experience with the use of medications for thyroid diseases and your feedback regarding this process.

Thank you for helping us gather this important information to promote the health of thyroid patients.

Part One

1) Do you prescribe Levothyroxine (LT4)?

LT4 prescriptions per week in a calendar year.

2) Do you prescribe Liothyronine (LT3)?

LT3 prescriptions per week in a calendar year.

3) Do you prescribe Thyroid Extract (Thyroid USP)?

Thyroid USP prescriptions per week in a calendar year.

4) I suspect an adverse event in a patient taking:

Levothyroxine (LT4)

Liothyronine (T3)

Thyroid Extract (Thyroid USP)

I did not perceive an adverse event.

Your Name*:

Your E-mail*:

*Optional - The ATA will not use your email address for any reason, including correspondence from the ATA.
The purpose of recording your name and email address is to validate our survey data for research purposes.